Oligonucleotide (siRNA) · developed by AMGEN
Olpasiran (AMG 890) is an agent given by subcutaneous injection every 12 weeks. It is studied in atherosclerotic cardiovascular disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05581303 | Phase 3 | Atherosclerotic Cardiovascular Disease | Active not recruiting | AMGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Atherosclerotic Cardiovascular Disease
Updated Nov 1, 2026. Something wrong or missing? Report it on the AMGN page.
See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AMGN catalysts and pipeline →